m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT05833				[1]
m⁶A modification SREBF2-AS1 SREBF2-AS1 METTL3 Methylation : m⁶A sites Direct Enhancement Non-coding RNA SREBF2-AS1 FXR1 lncRNA miRNA circRNA
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	SREBF2 antisense RNA 1 (SREBF2-AS1)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Non-coding RNA (ncRNA)
Epigenetic Regulator	SREBF2 antisense RNA 1 (SREBF2-AS1)			LncRNA	View Details
Regulated Target	FMR1 autosomal homolog 1 (FXR1)				View Details
Crosstalk Relationship	m6A → ncRNA			Enhancement
Crosstalk Mechanism	ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary	METTL3 and METTL14-induced m6A modification upregulated SREBF2 antisense RNA 1 (SREBF2-AS1) expression through increasing SREBF2-AS1 transcript stability. m6A-modified SREBF2-AS1 bound and recruited m6A reader FMR1 autosomal homolog 1 (FXR1) and DNA 5-methylcytosine dioxygenase TET1 to SREBF2 promoter, leading to DNA demethylation at SREBF2 promoter and the upregulation of SREBF2 transcription.
Responsed Disease	Acute myeloid leukaemia		ICD-11: 2A60		Disease Info
Responsed Drug	Chidamide				Drug Info
In-vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens		CVCL_0002
	HEL	Erythroleukemia	Homo sapiens		CVCL_0001
	MOLM-13	Adult acute myeloid leukemia	Homo sapiens		CVCL_2119
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens		CVCL_0064
	Kasumi-1	Myeloid leukemia with maturation	Homo sapiens		CVCL_0589
	HS-5	N.A.	Homo sapiens		CVCL_3720

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

2A60: Acute myeloid leukaemia		283 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Atezolizumab		Approved	[2]
External Link	TTD: D0YM2K
Compound Name	ENASIDENIB MESYLATE		Approved	[3]
Synonyms	UNII-UF6PC17XAV; AG-221 mesylate; Enasidenib (mesylate); UF6PC17XAV; Enasidenib mesylate [USAN]; Enasidenib mesylate (USAN); Enasidenib mesilate; Enasidenib methanesulfonate; Idhifa (TN); SCHEMBL16448052; HY-18690A; CS-7541 Click to Show/Hide
External Link	CID: 90480031 TTD: D0WH4P
Compound Name	Lestaurtinib		Approved (orphan drug)	[4]
Synonyms	A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN) Click to Show/Hide
External Link	CID: 126565 TTD: D0V9WF DrugBank: DB06469
Compound Name	Motixafortide		Approved	[5]
External Link	CID: 91865076 TTD: D0T6CN DrugBank: DB14939
Compound Name	ARN-509		Approved	[6]
Synonyms	Arn-509 (AR inhibitor) Click to Show/Hide
External Link	CID: 24872560 TTD: D0S7LG DrugBank: DB11901
Compound Name	DEOXYCYTIDINE		Approved	[7]
Synonyms	Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993 Click to Show/Hide
External Link	CID: 13711 TTD: D0RX7Z DrugBank: DB02594
Compound Name	Bestatin		Approved	[8]
Synonyms	Bestatin (TN); CHEBI:3070; UPCMLD-DP116; CHEMBL476869; SureCN25971; Ubenimex (JP16/INN); Ubenimex (JP17/INN); SCHEMBL25971; GTPL5151; AC1L972Z; UPCMLD-DP116:001; DTXSID4048430; CHEBI:140702; ZINC1532730; ZINC01532730; BDBM50010142; AKOS026750073; NCGC00161660-01; C00732; D00087; ((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl)-D-leucine; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid; (2R)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butanoyl]amino]-4-methyl-pentanoic acid Click to Show/Hide
External Link	CID: 72172 TTD: D0RA5Q DrugBank: DB03424
Compound Name	Tagraxofusp		Approved	[6]
Synonyms	Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor Click to Show/Hide
External Link	TTD: D0R7NI
Compound Name	Uracil mustard		Approved	[9]
Synonyms	Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol Click to Show/Hide
External Link	CID: 6194 TTD: D0J9UN DrugBank: DB00791
Compound Name	Tisagenlecleucel		Application submitted	[10]
Synonyms	Tisagenlecleucel-T Click to Show/Hide
External Link	TTD: D0IM6T
Compound Name	Olutasidenib		Approved	[2]
Synonyms	NEQYWYXGTJDAKR-JTQLQIEISA-N; Olutasidenib; UNII-0T4IMT8S5Z; 0T4IMT8S5Z; (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; Olutasidenib [USAN]; SCHEMBL17603134; HY-114226; CS-0080183; 5-(((1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile; 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-; 1887014-12-1 Click to Show/Hide
External Link	CID: 118955396 TTD: D07VYP
Compound Name	Midostaurin		Approved	[11]
Synonyms	PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251 Click to Show/Hide
External Link	CID: 9829523 TTD: D07NVU DrugBank: DB06595
Compound Name	Quizartinib		Approved	[12]
Synonyms	Quizartinib Click to Show/Hide
External Link	CID: 24889392 TTD: D07KYT DrugBank: DB12874
Compound Name	Ivosidenib		Approved	[12]
Synonyms	UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767 Click to Show/Hide
External Link	CID: 71657455 TTD: D07DCG DrugBank: DB14568
Compound Name	Gemtuzumab ozogamicin		Approved	[13]
Synonyms	Mylotarg (TN) Click to Show/Hide
External Link	TTD: D06EWO
Compound Name	Gilteritinib		Approved	[6]
Synonyms	UNII-66D92MGC8M; 66D92MGC8M; Gilteritinib [USAN:INN]; Gilteritinib(ASP2215); Gilteritinib (USAN/INN); Gilteritinib (ASP2215); Gilteritinib (ASP-2215); SCHEMBL282229; GTPL8708; MolPort-038-934-933; BDBM144315; C29H44N8O3; 3694AH; s7754; AKOS030234455; ZINC113476229; DB12141; CS-3885; KS-0000064E; AS-35199 Click to Show/Hide
External Link	CID: 49803313 TTD: D04KZY DrugBank: DB12141
Compound Name	Thioguanine		Approved	[14]
Synonyms	6-thioguanine; Lanvis; THG; Tabloid; ThioguaninGSK; Tioguanin; Tioguanina; Tioguanine; Tioguaninum; Glaxo Wellcome Brand of Thioguanine; Glaxo Wellcome Brand of Tioguanine; GlaxoSmithKline Brand of Thioguanine; GlaxoSmithKline Brand of Tioguanine; Thioguanin GSK; Thioguanine Hemihydrate; Thioguanine Monosodium Salt; Thioguanine Tabloid; Tioguanina Wellcome; Tioguanine GlaxoSmithKline Brand; Wellcome Brand of Thioguanine; BW 5071; DX4; LT00455187; Wellcome U3B; Lanvis (TN); Thioguanin-GSK; Thioguanine [USAN:BAN]; Tioguanina[INN-Spanish]; Tioguanine (INN); Tioguaninum [INN-Latin]; Purine antimetabolite: antimetabolite: inhibits nucleic acid replication; Guanine, thio-(VAN); 2 Amino 6 Purinethiol; 2-Amino 6MP; 2-Amino-1,7-dihydro-6H-purin-6-thion; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-Amino-6-MP; 2-Amino-6-mercaptopurine; 2-Amino-6-merkaptopurin; 2-Amino-6-merkaptopurin [Czech]; 2-Amino-6-purinethiol; 2-Amino-9H-purine-6-thiol; 2-Aminopurin-6-thiol; 2-Aminopurin-6-thiol [Czech]; 2-Aminopurine-6(1H)-thione; 2-Aminopurine-6-thiol; 2-Thioguanine; 2-amino-3,7-dihydropurine-6-thione; 6 Thioguanine; 6-Mercapto-2-aminopurine; 6-Mercaptoguanine; 6-TG; 6-Thioguanine (6-TG); 6-Thioguanine, Thioguanine; Thioguanine (Guanine analog) Click to Show/Hide
External Link	CID: 2723601 TTD: D02ZXM DrugBank: DB00352
Compound Name	Daunorubicin		Approved	[15]
Synonyms	Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline Click to Show/Hide
External Link	CID: 30323 TTD: D01XWG DrugBank: DB00694
Compound Name	Idarubicin		Approved	[16]
Synonyms	DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin Click to Show/Hide
External Link	CID: 42890 TTD: D01XDL DrugBank: DB01177
Compound Name	Aclarubicin		Approved	[17]
Synonyms	Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A Click to Show/Hide
External Link	CID: 451415 TTD: D01UBX DrugBank: DB11617
Compound Name	Magrolimab		Phase 3	[18]
Synonyms	GS-4721 Click to Show/Hide
External Link	TTD: DN5CM6
Compound Name	DSP-7888		Phase 2	[2]
External Link	TTD: DE5L6B
Compound Name	131I-labelled aCD45		Phase 3	[19]
External Link	TTD: DC8EN0
Compound Name	ATIR101		Phase 3	[20]
External Link	TTD: D6O2PN
Compound Name	Dociparstat sodium		Phase 3	[21]
Synonyms	DSTAT Click to Show/Hide
External Link	TTD: D5VRX2
Compound Name	Iomab-B CD45		Phase 3	[2]
External Link	TTD: D0Z0MI
Compound Name	Tasisulam		Phase 3	[22]
Synonyms	Tasisulam sodium; LY-573636; LY-573636 sodium; LY-573636Na; Apoptosis stimulator (cancer), Lilly Click to Show/Hide
External Link	CID: 10160238 TTD: D0X0KM DrugBank: DB11941
Compound Name	Vadastuximab talirine		Phase 3	[10]
Synonyms	Vadastuximab talirine [INN]; Vadastuximab talirine [USAN]; Vadastuximab talirine [WHO-DD]; UNII-T13V17U431; T13V17U431; UNII-X1TW58ZV0U component BNJNAEJASPUJTO-DUOHOMBCSA-N; 1436390-64-5 Click to Show/Hide
External Link	CID: 122706909 TTD: D0W2BF
Compound Name	Abexinostat		Phase 3	[2]
Synonyms	PCI-24781; 783355-60-2; PCI 24781; CRA-024781; CRA 024781; UNII-IYO470654U; 3-((dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)phenoxy)ethyl)benzofuran-2-carboxamide; CRA-02478; Abexinostat(PCI-24781); PCI-24781 (Abexinostat); Abexinostat (PCI-24781); IYO470654U; 3-[(Dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)carbonyl]phenoxy]ethyl]-2-benzofurancarboxamide; 3-((Dimethylamino)methyl)-N-(2-(4-(hydroxycarbamoyl)-phenoxy)ethyl)benzofuran-2-carboxamide Click to Show/Hide
External Link	CID: 11749858 TTD: D0V0SL DrugBank: DB12565
Compound Name	Peginterferon lambda-1a		Phase 3	[23]
Synonyms	BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb Click to Show/Hide
External Link	TTD: D0T6IN
Compound Name	CPX-351		Phase 3	[12]
Synonyms	Vyxeos; Cytarabine / daunonubicin; Daunonubicin / cytarabine; CPX 351; Cytarabine mixture with daunonubicin; Daunonubicin mixture with cytarabine; Daunonubicin and cytarabine liposomal injection; SCHEMBL3959238; 1256639-86-7; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-, mixt. with 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone Click to Show/Hide
External Link	CID: 11422859 TTD: D0SB1B
Compound Name	BYM338		Phase 2/3	[24]
External Link	TTD: D0S5FF
Compound Name	SGI110		Phase 3	[25]
External Link	CID: 137295284 TTD: D0Q5KZ
Compound Name	Elacytarabine		Phase 3	[26]
Synonyms	Elacyt (TN) Click to Show/Hide
External Link	CID: 6438895 TTD: D0PY5D DrugBank: DB05494
Compound Name	RG7388		Phase 3	[27]
Synonyms	Idasanutlin; 1229705-06-9; Idasanutlin (RG-7388); RG-7388; UNII-QSQ883V35U; QSQ883V35U; CHEMBL2402737; Benzoic acid, 4-((((2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl)carbonyl)amino)-3-methoxy-; RO5503781; Idasanutlin [USAN:INN]; Benzoic acid, 4-[[[(2R,3S,4R,5S)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)-2-pyrrolidinyl]carbonyl]amino]-3-methoxy-; RG-7388;Idasanutlin; RO-5503781; SCHEMBL442856 Click to Show/Hide
External Link	CID: 53358942 TTD: D0OC4O DrugBank: DB12325
Compound Name	Galinpepimut-S		Phase 3	[28]
External Link	TTD: D0M9OO
Compound Name	Pracinostat		Phase 3	[12]
Synonyms	929016-96-6; SB939; SB 939; Pracinostat (SB939); SB-939; UNII-GPO2JN4UON; GPO2JN4UON; CHEMBL1851943; (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide; 2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-; Pracinostat [INN]; (2E)-3-(2-Butyl-1-[2-(diethylamino)ethyl]-1h-1,3-benzodiazol-5-yl)-n-hydroxyprop-2-enamide; 2-Propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzimidazol-5-yl)-N-hydroxy-, (2E)- Click to Show/Hide
External Link	CID: 49855250 TTD: D0L2UQ DrugBank: DB05223
Compound Name	DFP-10917		Phase 3	[2]
External Link	CID: 119184 TTD: D0KE1F DrugBank: DB11667
Compound Name	AG-881		Phase 1	[2]
Synonyms	Vorasidenib; 1644545-52-7; UNII-789Q85GA8P; 789Q85GA8P; AG881; 9UO; 6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine; Vorasidenib [INN]; Vorasidenib (AG-881); SCHEMBL16393139; AG 881 [WHO-DD]; QCZAWDGAVJMPTA-RNFRBKRXSA-N; BDBM279948; EX-A2574; US10028961, Compound 101; AG 881; s8611; CS-8033; HY-104042; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoro propan-2-yl)-1,3,5-triazine-2,4-diamine; 6-(6-chloropyridin-2-yl)-N2,N4-bis((R)-1,1,1-trifluoroprop Click to Show/Hide
External Link	CID: 117817422 TTD: D0K9PC
Compound Name	AG-221		Phase 1/2	[29]
Synonyms	AG-221 (IDH2 inhibitor) Click to Show/Hide
External Link	CID: 89683805 TTD: D0K7FT DrugBank: DB13874
Compound Name	CP-868596		Phase 3	[2]
Synonyms	Crenolanib; 670220-88-9; Crenolanib (CP-868596); ARO-002; UNII-LQF7I567TQ; LQF7I567TQ; CP-868596 (Crenolanib); CP-868,596; [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine; 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine; CP868569; 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine; J-502712; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Click to Show/Hide
External Link	CID: 10366136 TTD: D0J1GR DrugBank: DB11832
Compound Name	Rydaptmidostaurin		Phase 3	[2]
External Link	TTD: D0H6BS
Compound Name	Sapacitabine		Phase 3	[30]
Synonyms	CYC682 Click to Show/Hide
External Link	CID: 153970 TTD: D0D4RF DrugBank: DB06365
Compound Name	S-110		Phase 3	[25]
Synonyms	DNA demethylating agent (myelodysplastic syndrome), Supergen Click to Show/Hide
External Link	TTD: D0A2BO
Compound Name	VAL-083		Phase 1/2	[31]
Synonyms	Dianhydrogalactitol; 23261-20-3; UNII-4S465RYF7M; 1,2:5,6-DIANHYDROGALACTITOL; Dulcitoldiepoxide; 4S465RYF7M; Dianhydrogalactitol [USAN:INN]; SCHEMBL4306431; Dianhydrogalactitol (USAN/INN); CHEMBL3137322; AAFJXZWCNVJTMK-GUCUJZIJSA-N; ZINC4963497; CS-1358; DB12873; NSC-1323313; HY-16513; BC657197; D10623; W-5268; J-015059; 457899-38-6 Click to Show/Hide
External Link	CID: 15942827 TTD: D0A1IL DrugBank: DB12873
Compound Name	CC-486		Phase 3	[2]
Synonyms	AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue Click to Show/Hide
External Link	CID: 9840076 TTD: D09NTC
Compound Name	Hu5F9-G4		Phase 3	[10]
External Link	TTD: D09JYL
Compound Name	Iomab-B		Phase 3	[32]
Synonyms	Iomab-B (TN) Click to Show/Hide
External Link	TTD: D08BBL
Compound Name	PEG arginine deiminase		Phase 1	[2]
Synonyms	ADI-PEG 20 Click to Show/Hide
External Link	TTD: D07UAS
Compound Name	CPI-613		Phase 3	[12]
Synonyms	95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874 Click to Show/Hide
External Link	CID: 24770514 TTD: D07NVI DrugBank: DB12109
Compound Name	Zarnestra		Phase 3	[33]
Synonyms	JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE Click to Show/Hide
External Link	CID: 159324 TTD: D07NPS DrugBank: DB04960
Compound Name	LMT-X		Phase 3	[34]
Synonyms	Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx Click to Show/Hide
External Link	TTD: D05XDZ
Compound Name	Elesclomol		Phase 3	[35]
Synonyms	488832-69-5; Elesclomol (STA-4783); STA-4783; UNII-6UK191M53P; CHEBI:79369; 6UK191M53P; Propanedioic acid, bis[2-methyl-2-(phenylthioxomethyl)hydrazide]; 1,3-Bis[2-methyl-2-(phenylthioxomethyl)hydrazide]propanedioic acid; N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide; J-503879; C19H20N4O2S2; 1-N'-Benzenecarbothioyl-3-(2-benzenecarbothioyl-2-methylhydrazinyl)-N'-methyl-oxopropanehydrazidide; Elesclomol [USAN:INN]; elesclomolum Click to Show/Hide
External Link	CID: 300471 TTD: D05IRV DrugBank: DB05719
Compound Name	GMI-1271		Phase 3	[36]
Synonyms	Uproleselan Click to Show/Hide
External Link	CID: 71600085 TTD: D03PWD DrugBank: DB14829
Compound Name	AT-406		Phase 3	[37]
Synonyms	1071992-99-8; SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; CHEMBL2158051; QCR-136; UNII-N65WC8PXDD; N65WC8PXDD; AT406 (SM-406, ARRY-334543); J-501625; (5S,8S,10aR)-N-(Diphenylmethyl)-5-[(N-methyl-L-alanyl)amino]-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide; AT-406/Debio-1143 Click to Show/Hide
External Link	CID: 25022340 TTD: D03MXK
Compound Name	PR1 peptide antigen vaccine		Phase 3	[38]
Synonyms	PR1 peptide antigen vaccine (leukemia); PR1 peptide antigen vaccine (leukemia), MD Anderson; PR1 peptide antigen vaccine (leukemia), Vaccine Company Click to Show/Hide
External Link	TTD: D03GHV
Compound Name	CPI-0610		Phase 3	[2]
External Link	CID: 57389999 TTD: D01LVE
Compound Name	SNS-595		Phase 3	[39]
Synonyms	Voreloxin; Vosaroxin; AG 7352; SNS 595; SPC 595; AG 7352 (TN); AG-7352; SNS 595 (TN); SPC 595 (TN); SPC-595; Voreloxin (TN); Voreloxin (USAN); SNS-595 (TN); 1,4-Dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid Click to Show/Hide
External Link	CID: 9952884 TTD: D00NVM DrugBank: DB11999
Compound Name	Selinexor		Phase 3	[12]
Synonyms	Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F Click to Show/Hide
External Link	CID: 71481097 TTD: D00LNW DrugBank: DB11942
Compound Name	Volasertib		Phase 3	[12]
Synonyms	755038-65-4; BI 6727; BI-6727; BI6727 (Volasertib); Volasertib (BI 6727); UNII-6EM57086EA; 6EM57086EA; BI6727; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI6727 (Volasertib)/; BI 6727 (Volasertib); MLS006011195; SCHEMBL738946; SCHEMBL9888052; SCHEMBL2169101; GTPL7947 Click to Show/Hide
External Link	CID: 10461508 TTD: D00BYM DrugBank: DB12062
Compound Name	Rivo-cel		Phase 2/3	[40]
Synonyms	BPX-501 Click to Show/Hide
External Link	TTD: D4OU6H
Compound Name	CLL1 CAR-T Cell		Phase 2/3	[41]
External Link	TTD: D0RF4J
Compound Name	NLG8189		Phase 2/3	[2]
Synonyms	1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189 Click to Show/Hide
External Link	CID: 405012 TTD: D0B5HS DrugBank: DB12827
Compound Name	CD123/CLL1 CAR-T Cells		Phase 2/3	[41]
External Link	TTD: D04GGG
Compound Name	K-NK002		Phase 2	[42]
Synonyms	CSTD-002-NK Click to Show/Hide
External Link	TTD: DTU7W2
Compound Name	Dilanubicel		Phase 2	[43]
Synonyms	NLA101 Click to Show/Hide
External Link	TTD: DS01GZ
Compound Name	DS-3201b		Phase 2	[44]
Synonyms	Valemetostat; 1809336-39-7; UNII-60RD0234VE; 60RD0234VE; 1809336-39-7 (free base); DS-3201; (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide; Valemetostat 2HCl; Valemetostat [INN]; Valemetostat (DS-3201); CHEMBL4597193; EZH1/2 inhibitor DS-3201; SCHEMBL18393626; SCHEMBL18393627; SCHEMBL18639210; EX-A3423; DS3201; NSC813381; s8926; NSC-813381; HY-109108; CS-0039740; D11551 Click to Show/Hide
External Link	CID: 126481870 TTD: DNM79H
Compound Name	BST-236		Phase 2	[45]
Synonyms	Aspacytarabine; UNII-JL7V54Z2BR; JL7V54Z2BR; 2098942-53-9; N4-(1-beta-D-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)-; Astarabine; Aspacytarabine [INN]; CHEMBL4297599; L-Asparagine, N-(1-beta-D-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-; N4-(1-N2-D-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin-4-yl)- L-asparagine Click to Show/Hide
External Link	CID: 135390942 TTD: DGN26L
Compound Name	Zelenoleucel		Phase 2	[46]
External Link	TTD: D4T8JV
Compound Name	CX-01		Phase 2	[2]
External Link	TTD: D0ZI4L
Compound Name	LY2090314		Phase 2	[47]
Synonyms	603288-22-8; LY-2090314; UNII-822M3GYM67; Kinome_3681; LY 2090314; CHEMBL362558; 822M3GYM67; 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione; SCHEMBL633455; GTPL7958; DTXSID90209085; MolPort-035-944-332; EX-A2214; ZINC3817327; BCP07855; s7063; BDBM50150699; AKOS032950045; AKOS026750195; CS-1633; DB11913; SB16558; NCGC00378942-05; NCGC00378942-02; BC600682; QC-11735; HY-16294; KB-78238; FT-0698670; LY2090314, &gt Click to Show/Hide
External Link	CID: 10029385 TTD: D0Z1DH DrugBank: DB11913
Compound Name	Flotetuzumab		Phase 2	[48]
External Link	TTD: D0YA1B
Compound Name	BGB-324		Phase 1/2	[12]
Synonyms	BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio Click to Show/Hide
External Link	TTD: D0X9VR
Compound Name	PTX-200		Phase 2	[2]
Synonyms	Plant-derived antiparkinsonian, Phytrix Click to Show/Hide
External Link	TTD: D0X7CV
Compound Name	LY2523355		Phase 2	[49]
Synonyms	Litronesib Click to Show/Hide
External Link	CID: 25167017 TTD: D0W9SL DrugBank: DB11861
Compound Name	Prexigebersen		Phase 2	[2]
Synonyms	Prexigebersen [INN]; Prexigebersen [USAN:INN]; UNII-8W1O4Y961B; 8W1O4Y961B; BP-100-1.01/L-Grb2; DNA, d(A-T-A-T-T-T-G-G-C-G-A-T-G-G-C-T-T-C); 202484-91-1; 1352967-54-4 Click to Show/Hide
External Link	CID: 123132008 TTD: D0W3GR
Compound Name	ALT-801		Phase 2	[50]
Synonyms	ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor Click to Show/Hide
External Link	TTD: D0V5JH
Compound Name	ENMD-2076		Phase 2	[51]
Synonyms	934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159 Click to Show/Hide
External Link	CID: 16041424 TTD: D0S7HM
Compound Name	FPI-01		Phase 2	[52]
Synonyms	WT-1 therapeutic vaccine (cancer), Formula Pharmaceuticals Click to Show/Hide
External Link	TTD: D0RG8Z
Compound Name	Inecalcitol oral		Phase 2	[2]
Synonyms	Inecalcitol; TX-522; UNII-05FZV98342; TX 522; 163217-09-2; AC1OCD0K; 19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3; 05FZV98342; (1R,3R)-5-[(2E)-2-[(1R,3aR,7aR)-1-[(2R)-6-hydroxy-6-methylhept-4-yn-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; (7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol; Inecalcitol [INN]; SCHEMBL754593; GTPL7747; CHEMBL2105107; LMST03020649; 8151AH; ZINC12504514; AKOS025312295; AN-7569; DB04796; TX-527; Vitamin D analogs, Catholic University of Leuven; Vitamin D analogs, KULeuven; Inecalcitol (oral, hyperthyroidism), Hybrigenics; Inecalcitol (sc, psoriasis), Hybrigenics; Vitamin D analog (sc, psoriasis), Hybrigenics; Inecalcitol (oral, prostate cancer/psoriasis), Hybrigenics Click to Show/Hide
External Link	CID: 6915835 TTD: D0R8IE DrugBank: DB04796
Compound Name	Eryaspase		Phase 2	[2]
External Link	TTD: D0P0SD
Compound Name	ALXN6000		Phase 2	[10]
Synonyms	Samalizumab Click to Show/Hide
External Link	TTD: D0OY9L
Compound Name	BI 2536		Phase 2	[53]
Synonyms	BI2536, BI 2536 Click to Show/Hide
External Link	CID: 11364421 TTD: D0O0LQ
Compound Name	MK8242		Phase 2	[54]
External Link	TTD: D0NT6P
Compound Name	Leukemia DNA vaccine		Phase 2	[55]
External Link	TTD: D0N6UA
Compound Name	Anti-CD45 mAb 131I-BC8		Phase 2	[12]
External Link	TTD: D0N4NH
Compound Name	BREQUINAR		Phase 1/2	[56]
Synonyms	96187-53-0; 6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid; brequinarum [Latin]; Brequinar [INN]; Biphenquinate; 6-fluoro-2-(2'-fluorobiphenyl-4-yl)-3-methylquinoline-4-carboxylic acid; Brequinarum [INN-Latin]; UNII-5XL19F49H6; C23H15F2NO2; NSC-368390; NSC 368390; 6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid; PHEZJEYUWHETKO-UHFFFAOYSA-N; Dup 785; 5XL19F49H6; 6-FLUORO-2-(2'-FLUORO-1,1'-BIPHENYL-4-YL)-3-METHYLQUINOLINE-4-CARBOXYLIC ACID; brequinarum Click to Show/Hide
External Link	CID: 57030 TTD: D0N3XT DrugBank: DB03523
Compound Name	Leukemia cancer vaccine		Phase 2	[57]
External Link	TTD: D0M0OT
Compound Name	ADCT-301		Phase 1	[2]
Synonyms	camidanlumab tesirine Click to Show/Hide
External Link	TTD: D0LL1N
Compound Name	Flavopiridol		Phase 2	[12]
Synonyms	FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one Click to Show/Hide
External Link	CID: 5287969 TTD: D0LF1U DrugBank: DB03496
Compound Name	BP-100-1-01		Phase 2	[58]
External Link	TTD: D0L3KA
Compound Name	IRX-2		Phase 2	[59]
External Link	TTD: D0KS6F
Compound Name	Cenersen		Phase 2	[60]
External Link	CID: 56841947 TTD: D0K4VW
Compound Name	Lirilumab		Phase 2	[61]
External Link	TTD: D0I7PU
Compound Name	LOR-2040		Phase 2	[62]
External Link	TTD: D0I7NG
Compound Name	Sodium butyrate		Phase 2	[63]
Synonyms	Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA) Click to Show/Hide
External Link	CID: 5222465 TTD: D0I7IB
Compound Name	GRNVAC1		Phase 2	[64]
External Link	TTD: D0I6RI
Compound Name	H3B-8800		Phase 1	[2]
External Link	TTD: D0H7BF
Compound Name	GS-9973		Phase 2	[2]
Synonyms	Entospletinib; 1229208-44-9; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385 Click to Show/Hide
External Link	CID: 59473233 TTD: D0G9AW DrugBank: DB12121
Compound Name	ALT-803		Phase 2	[65]
Synonyms	IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience Click to Show/Hide
External Link	TTD: D0FD7H
Compound Name	CHR-2797		Phase 2	[66]
Synonyms	Tosedostat; Tosedostat, CHR2797, CHR-2797 Click to Show/Hide
External Link	CID: 15547703 TTD: D0F2JS DrugBank: DB11781
Compound Name	HTERT RNA vaccine		Phase 2	[67]
External Link	TTD: D0CQ1X
Compound Name	MB-102		Phase 2	[10]
Synonyms	Relmapirazin; UNII-Q3UQB8PQ6H; Q3UQB8PQ6H; Relmapirazin [INN]; CHEMBL1949708; SCHEMBL16738795; N,N'-((3,6-Diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine); D-Serine, N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-; 1313706-17-0 Click to Show/Hide
External Link	CID: 53389120 TTD: D0C3JB
Compound Name	phorbol 12-myristate 13-acetate		Phase 2	[2]
Synonyms	TPA; 12-O-tetradecanoylphorbol-13-acetate; tetradecanoyl-beta-phorbol acetate Click to Show/Hide
External Link	CID: 27924 TTD: D09DHT
Compound Name	AEB1102		Phase 1	[2]
External Link	TTD: D08WQU
Compound Name	Ifabotuzumab		Phase 2	[10]
External Link	TTD: D08NZG
Compound Name	BP1001		Phase 2	[12]
External Link	TTD: D08IVF
Compound Name	AS-101		Phase 2	[68]
Synonyms	Ossirene; Tellaxium trichloride glycol; IVX-Q-101 Click to Show/Hide
External Link	CID: 11260998 TTD: D08EAI
Compound Name	ALRN-6924		Phase 2	[2]
External Link	TTD: D07UKT
Compound Name	GO-203-2c		Phase 2	[2]
External Link	TTD: D07OAD
Compound Name	Talacotuzumab		Phase 2	[10]
Synonyms	JNJ 473; JNJ 56022473; TAL Click to Show/Hide
External Link	TTD: D07MGC
Compound Name	AST-VAC1		Phase 2	[69]
External Link	TTD: D07KAB
Compound Name	Lomab B		Phase 2	[70]
Synonyms	BCS-I-131 construct Click to Show/Hide
External Link	TTD: D07CQW
Compound Name	Fipamezole		Phase 2	[71]
Synonyms	150586-58-6; JP-1730; 1H-Imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-; Fipamezole [INN]; ACMC-1BZQD; AC1Q4NYS; SCHEMBL935549; AC1L4U51; SCHEMBL18826053; CHEMBL1255582; CTK4C6705; 5-(2-ethyl-5-fluoro-1,3-dihydroinden-2-yl)-1H-imidazole; KXSUAWAUCNFBQJ-UHFFFAOYSA-N; 5-(2-ethyl-5-fluoro-2,3-dihydro-1h-inden-2-yl)-1h-imidazole; BDBM50417007; SB17014; 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole; L001472; 4-((2RS)-2-Ethyl-5-fluoroindan-2-yl)-1H-imidazole Click to Show/Hide
External Link	CID: 213041 TTD: D05LGX DrugBank: DB06585
Compound Name	PR104		Phase 2	[72]
Synonyms	851627-62-8; PR-104; UNII-V16D2ZT7DT; V16D2ZT7DT; 2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate; 2-[(2-bromoethyl)(2,4-dinitro-6-{[2-(phosphonooxy)ethyl]carbamoyl}phenyl)amino]ethyl methanesulfonate; PR 104; SCHEMBL367963; ZINC43131754; AKOS022174966; RL05275; KB-80083; 4CA-1041; AX8282408; J-507569; Benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-3,5- dinitro-N-(2-(phosphonooxy)ethyl)- Click to Show/Hide
External Link	CID: 11455973 TTD: D05CFG DrugBank: DB05968
Compound Name	BI-836858		Phase 1/2	[2]
External Link	TTD: D04MGW
Compound Name	Ficlatuzumab		Phase 2	[2]
Synonyms	AV-299 Click to Show/Hide
External Link	TTD: D03UBW
Compound Name	K562/GM-CSF		Phase 2	[73]
Synonyms	GM-CSF-secreting cells+tumor cell vaccine, Cell Genesys/Johns Hopkins Click to Show/Hide
External Link	TTD: D03PRC
Compound Name	PCM-075		Phase 2	[2]
Synonyms	Onvansertib Click to Show/Hide
External Link	CID: 49792852 TTD: D03HUX DrugBank: DB15110
Compound Name	Actimab-A		Phase 2	[10]
External Link	TTD: D03HSA
Compound Name	IMG-7289		Phase 2	[2]
Synonyms	KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide Click to Show/Hide
External Link	CID: 122460381 TTD: D03EOZ DrugBank: DB15126
Compound Name	WT1-targeted autologous dendritic cell vaccine		Phase 2	[74]
Synonyms	WT1-targeted autologous dendritic cell vaccine (cancer) Click to Show/Hide
External Link	TTD: D02MLO
Compound Name	AZD-4877		Phase 2	[75]
Synonyms	Anticancer therapeutic (solid tumors), AstraZeneca Click to Show/Hide
External Link	CID: 10368812 TTD: D02AAO DrugBank: DB11671
Compound Name	IPH-2102		Phase 2	[76]
External Link	TTD: D00RYU
Compound Name	ASP7517		Phase 1/2	[77]
External Link	TTD: DYM1J4
Compound Name	CG-806		Phase 1/2	[78]
Synonyms	1370466-81-1; UNII-7W3FGR71NN; 7W3FGR71NN; 1-(3-fluoro-4-(7-(4-methyl-1H-imidazol-2-yl)-1-oxoisoindolin-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea; SCHEMBL1292507; EX-A2932; NSC810717; CG'806; NSC-810717; CG-026806; HY-112646; CS-0058852; 1-(3-Fluoro-4-(7-(5-methyl-1H-imidazol-2-yl)-1-oxo-2,3-dihydro-1H-isoindo-1-4-yl)-phenyl)-3-(3-trifluoromethyl-phenyl)urea; Urea, N-(4-(2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl)-3-fluorophenyl)-N'-(3-(trifluoromethyl)phenyl)- Click to Show/Hide
External Link	CID: 66981446 TTD: DT3BA1
Compound Name	KO-539		Phase 1/2	[79]
Synonyms	UNII-4MOD1F4ENC; 4MOD1F4ENC; SCHEMBL20846943; KO539; Menin-mll interaction inhibitor KO 539; (S)-4-Methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile; 2134675-36-6 Click to Show/Hide
External Link	CID: 138497449 TTD: DS4JE8
Compound Name	SAR440234		Phase 1/2	[80]
External Link	TTD: DL1FG3
Compound Name	HM43239		Phase 1/2	[81]
External Link	TTD: DI1VM3
Compound Name	Annamycin		Phase 1/2	[2]
Synonyms	92689-49-1; UNII-SNU299M83Q; 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin; SNU299M83Q; (7S,9S)-7-(((2R,3R,4R,5R,6S)-4,5-Dihydroxy-3-iodo-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7,8,9,10-tetrahydrotetracene-5,12-dione; AR-522; SCHEMBL19368; (7S,9S)-7-[(2R,3R,4R,5R,6S)-4,5-dihydroxy-3-iodo-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione; ZINC3918134; DB06420; 5,12-Naphthacenedione, 7-((2,6-dideoxy-2-iodo-alpha-L-mannopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, (7S-cis)-; 689A491; Q4767903 Click to Show/Hide
External Link	CID: 115212 TTD: DCT2Q3 DrugBank: DB06420
Compound Name	ONO-7475		Phase 1/2	[82]
Synonyms	1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Click to Show/Hide
External Link	CID: 90645873 TTD: DA1MG8
Compound Name	FF-10101		Phase 1/2	[83]
Synonyms	1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)- Click to Show/Hide
External Link	CID: 90052320 TTD: D28HJI
Compound Name	SL-401		Phase 1/2	[84]
External Link	TTD: D0Z2ZY
Compound Name	SEL-24		Phase 1/2	[2]
Synonyms	Multikinase inhibitor (cancer), Selvita; SEL-24-1; SEL-24-11; SEL-24-20; Pim-1 kinase inhibitors (cancer), Selvita Click to Show/Hide
External Link	TTD: D0X8ID
Compound Name	SEL24		Phase 1/2	[85]
Synonyms	MEN1703 Click to Show/Hide
External Link	TTD: D0V2ZC
Compound Name	CD38-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D0UJ3C
Compound Name	HuM-195-Ac-225		Phase 1/2	[87]
Synonyms	HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab Click to Show/Hide
External Link	TTD: D0TV6H
Compound Name	NEXI-001		Phase 1/2	[88]
External Link	TTD: D0SZT3
Compound Name	INCB59872		Phase 1/2	[2]
External Link	TTD: D0R7CD
Compound Name	MG7-CART		Phase 1/2	[89]
External Link	TTD: D0Q5GK
Compound Name	PRI-724		Phase 1/2	[90]
External Link	CID: 71509318 TTD: D0Q0ZY DrugBank: DB15034
Compound Name	CART-123 cells		Phase 1/2	[91]
External Link	TTD: D0N6PE
Compound Name	OXi4503		Phase 1/2	[2]
Synonyms	Combretastatin A-1 phosphate; 288847-34-7; Combretastatin A1 disodium phosphate; 1,2-Benzenediol, 3-methoxy-6-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, bis(dihydrogen phosphate), tetrasodium salt Click to Show/Hide
External Link	CID: 6918545 TTD: D0N4HQ
Compound Name	CIK-CAR.CD19		Phase 1/2	[2]
External Link	TTD: D0M2XK
Compound Name	RhH1.3		Phase 1/2	[92]
Synonyms	Oncohist; Histone H1, SymbioTec; Recombinant human histone H1.3, SymbioTec; RhH1.3, SymbioTec Click to Show/Hide
External Link	TTD: D0K6UG
Compound Name	JTCR016		Phase 1/2	[10]
External Link	TTD: D0J6AJ
Compound Name	Muc1-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D0IQ3E
Compound Name	Lintuzumab Ac-225		Phase 1/2	[93]
Synonyms	Actimab-A (TN) Click to Show/Hide
External Link	TTD: D0HV7A
Compound Name	CD33-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D0G9MY
Compound Name	CD19 specific CAR T cells		Phase 1/2	[94]
External Link	TTD: D0FR3J
Compound Name	EPZ-5676		Phase 1/2	[95]
Synonyms	pinometostat; 1380288-87-8; EPZ5676; UNII-8V9YR09EF3; UNII-F66X4M38G5; 8V9YR09EF3; CHEMBL3087499; CHEMBL3414626; F66X4M38G5; 1380288-88-9; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol; Pinometostat, trans-; 5'-[{cis-3-[2-(5-Tert-Butyl-1h-Benzimidazol-2-Yl)ethyl]cyclobutyl}(Propan-2-Yl)amino]-5'-Deoxyadenosine Click to Show/Hide
External Link	CID: 57345410 TTD: D0C6GK DrugBank: DB12920
Compound Name	BSK01		Phase 1/2	[10]
External Link	TTD: D0AZ1N
Compound Name	CNDO-109		Phase 1/2	[12]
External Link	TTD: D0A0CY
Compound Name	DT388IL-3		Phase 1/2	[96]
External Link	TTD: D08MKR
Compound Name	PLX2853		Phase 1/2	[97]
External Link	TTD: D07GHA
Compound Name	CWP232291		Phase 1/2	[98]
External Link	TTD: D07AYI
Compound Name	BPX-501		Phase 1/2	[2]
External Link	TTD: D06LYI
Compound Name	RTX-240		Phase 1/2	[99]
External Link	TTD: D05ZBV
Compound Name	G0-203-2c		Phase 1/2	[100]
External Link	TTD: D04WHM
Compound Name	CD123-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D04MLR
Compound Name	CD56-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D03HML
Compound Name	OTX-015		Phase 1/2	[101]
Synonyms	MK 8628 Click to Show/Hide
External Link	CID: 9936746 TTD: D02YNI DrugBank: DB15189
Compound Name	FF-10501-01		Phase 1/2	[2]
External Link	TTD: D02BVW
Compound Name	SGN-CD33A		Phase 1/2	[12]
External Link	TTD: D01KKI
Compound Name	CLL1-specific gene-engineered T cells		Phase 1/2	[86]
External Link	TTD: D00QWK
Compound Name	CLT030		Phase 1	[102]
External Link	TTD: DW01LJ
Compound Name	FT500		Phase 1	[103]
External Link	TTD: DSYM73
Compound Name	225Ac-labelled aCD33		Phase 1	[104]
External Link	TTD: DSI4G9
Compound Name	PRGN-3006		Phase 1	[105]
External Link	TTD: DR0L8A
Compound Name	GEM333		Phase 1	[106]
External Link	TTD: DQD1T2
Compound Name	VOB560		Phase 1	[107]
Synonyms	S 65487 Click to Show/Hide
External Link	TTD: DP63FS
Compound Name	SEL120		Phase 1	[108]
Synonyms	SEL120-34A HCl; UNII-SDM3M518PJ; SDM3M518PJ; 1609452-30-3; SEL-120; SEL120-34A (monohydrochloride); SE-120-34A; 1609452-30-3 (HCl); 7,8-Dibromo-9-methyl-2-piperazin-1-yl-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline Hydrochloride; CHEMBL4578881; SCHEMBL17106021; s8840; EX-A2929-1; HY-111388A; BS-16042; CS-0041061; A17086; SEL120(SEL120-34,SEL120-34A); 4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1); 7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4himidazo(4,5,1-ij)quinoline hydrochloride Click to Show/Hide
External Link	CID: 73776232 TTD: DOJG79
Compound Name	NKX101		Phase 1	[109]
External Link	TTD: DOBZ63
Compound Name	AMG 673		Phase 1	[2]
External Link	TTD: DNS2P1
Compound Name	SAR443579		Phase 1	[110]
External Link	TTD: DMKG40
Compound Name	IO-202		Phase 1	[111]
External Link	TTD: DM9GO4
Compound Name	CYC140		Phase 1	[112]
Synonyms	Telparevir; Telaprevir - VX-950; SCHEMBL6468440; CS-M3592; ZINC164377440; (1S,3aR,6aS)-2-((R)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide; (3S,3aS,6aR)-2-[(2R)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide; Cyclopenta[c]pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(2-pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-2-oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- Click to Show/Hide
External Link	CID: 57336523 TTD: DK26FL
Compound Name	SKI-G-801		Phase 1	[113]
External Link	TTD: DIA08F
Compound Name	CC-90002		Phase 1	[10]
External Link	TTD: DI8WC4
Compound Name	TAS-1440		Phase 1	[114]
External Link	TTD: DI17KH
Compound Name	RG6007		Phase 1	[115]
External Link	TTD: DHWF68
Compound Name	CB-5339		Phase 1	[116]
External Link	TTD: DFC0V4
Compound Name	SAR445419		Phase 1	[117]
External Link	TTD: DCQ6L4
Compound Name	AB-110		Phase 1	[118]
External Link	TTD: DC6LS1
Compound Name	LP-108		Phase 1	[119]
External Link	TTD: DBY42T
Compound Name	H3B-8800		Phase 1	[120]
Synonyms	(2S,3S,6S,7R,10R,E)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate; 1825302-42-8; SCHEMBL17255784; DB14017 Click to Show/Hide
External Link	CID: 92135969 TTD: DB5O1U DrugBank: DB14017
Compound Name	CD123-CD33 Ccar		Phase 1	[121]
External Link	TTD: DB4C5H
Compound Name	JNJ-63709178		Phase 1	[2]
External Link	TTD: D9TG4H
Compound Name	JNJ-67571244		Phase 1	[122]
External Link	TTD: D9OZ3B
Compound Name	AMG 427		Phase 1	[123]
External Link	TTD: D91CMX
Compound Name	AMG 330		Phase 1	[2]
External Link	TTD: D8AOC1
Compound Name	ABBV-184		Phase 1	[124]
External Link	TTD: D7QHV6
Compound Name	MIK665		Phase 1	[125]
Synonyms	1799631-75-6; (2~{R})-2-[5-[3-chloranyl-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid; (R)-2-((5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; MIK-665; S-64315; SCHEMBL16815710; EX-A2912; NSC809971; NSC-809971; HY-112218; CS-0044179; (5R)-(R)-2-((5-(3-Chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((2-(2-methoxyphenyl)pyrimidin-4-yl)methoxy)phenyl)propanoic acid; 1799831-02-9; OK5 Click to Show/Hide
External Link	CID: 118157243 TTD: D7LC8N
Compound Name	FT538		Phase 1	[126]
External Link	TTD: D79JZU
Compound Name	BGB-11417		Phase 1	[127]
External Link	TTD: D74BRK
Compound Name	SEA-CD70		Phase 1	[128]
External Link	TTD: D6H9TE
Compound Name	CLL1-CD33 cCART cell therapy		Phase 1	[129]
External Link	TTD: D5T9GZ
Compound Name	KITE-222		Phase 1	[130]
External Link	TTD: D4UQ2B
Compound Name	CYAD-02		Phase 1	[131]
External Link	TTD: D2Z7EL
Compound Name	GDX012		Phase 1	[132]
External Link	TTD: D2V9RQ
Compound Name	APVO436		Phase 1	[133]
External Link	TTD: D2GY5C
Compound Name	LAM-003		Phase 1	[2]
External Link	TTD: D20IMG
Compound Name	IMGN779		Phase 1	[2]
External Link	TTD: D0ZR1Z
Compound Name	BPX-701		Phase 1	[10]
External Link	TTD: D0ZA1K
Compound Name	BMS-936564		Phase 1	[134]
External Link	TTD: D0Z8JR
Compound Name	UCART123		Phase 1	[2]
External Link	TTD: D0Z7QK
Compound Name	FF-10101-01		Phase 1	[2]
External Link	TTD: D0YQ9I
Compound Name	CART-56 cells		Phase 1	[135]
External Link	TTD: D0YH5L
Compound Name	AVB-S6-500		Phase 1	[2]
External Link	TTD: D0Y5QA
Compound Name	BB-MPI-03		Phase 1	[69]
External Link	TTD: D0W1TL
Compound Name	ONO-7475		Phase 1	[2]
External Link	TTD: D0VH4T
Compound Name	LC-1		Phase 1	[136]
Synonyms	Dimethylamino-parthenolide; Parthenolide analog (leukemia), Leuchemix Click to Show/Hide
External Link	TTD: D0V5AL
Compound Name	CART123 cells		Phase 1	[137]
External Link	TTD: D0R5NU
Compound Name	NKR-2 cells		Phase 1	[138]
External Link	TTD: D0QR2K
Compound Name	CART-33 cells		Phase 1	[135]
External Link	TTD: D0P6YN
Compound Name	BI-811283		Phase 1	[139]
External Link	TTD: D0P5IZ
Compound Name	INNO-305		Phase 1	[140]
External Link	TTD: D0P2ZY
Compound Name	IGN523		Phase 1	[141]
External Link	TTD: D0OQ5R
Compound Name	CART-34 cells		Phase 1	[135]
External Link	TTD: D0NY1Y
Compound Name	CM-CS1 T-cell		Phase 1	[142]
External Link	TTD: D0NC9M
Compound Name	Mivebresib		Phase 1	[2]
Synonyms	ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815 Click to Show/Hide
External Link	CID: 71600087 TTD: D0M2TS
Compound Name	AMV564		Phase 1	[2]
External Link	TTD: D0LP7U
Compound Name	SAR-103168		Phase 1	[143]
External Link	TTD: D0LO5N
Compound Name	DS-3201		Phase 1	[2]
Synonyms	QTGYNKYZRZATJB-UHFFFAOYSA-N; 701899-63-0; 2-(2-(2-Methyl-1H-imidazol-5-yl)ethyl)isoindoline-1,3-dione; 2-(2-(2-Methyl-1H-imidazol-5-yl)-ethyl)isoindoline-1,3-dione; SCHEMBL7743461; MolPort-035-945-474; MolPort-035-690-353; ZINC98086069; AKOS024459002; AKOS024262663; MCULE-2708350770; FCH4077443; AK158834; AX8292467; ST2403812; 2-[2-(2-methyl-1H-imidazol-5-yl)ethyl]-2,3-dihydro-1H-isoindole-1,3-dione Click to Show/Hide
External Link	CID: 22627096 TTD: D0LG8T
Compound Name	PF-06747143		Phase 1	[10]
External Link	TTD: D0LC5L
Compound Name	DCLL9718S		Phase 1	[2]
External Link	TTD: D0K6JZ
Compound Name	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells		Phase 1	[144]
External Link	TTD: D0JX7M
Compound Name	CSL-362		Phase 1	[145]
Synonyms	CSL-360; Monoclonal antibody (acute myelogenous leukemia), CSL; Therapeutic leukaemia antibody (AML), CSL; 7G3 Click to Show/Hide
External Link	TTD: D0JF9Z
Compound Name	AMG 176		Phase 1	[146]
Synonyms	JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)- Click to Show/Hide
External Link	CID: 118910268 TTD: D0I5DP
Compound Name	XmAb14045		Phase 1	[2]
External Link	TTD: D0I4BK
Compound Name	SY-1425		Phase 1	[2]
External Link	TTD: D0HY3D
Compound Name	AGS62P1		Phase 1	[2]
Synonyms	AGS-62P1 Click to Show/Hide
External Link	TTD: D0H3ND
Compound Name	CART-117 cells		Phase 1	[135]
External Link	TTD: D0E0SH
Compound Name	CART-Muc1 cells		Phase 1	[135]
External Link	TTD: D0DJ8S
Compound Name	BAY1436032		Phase 1	[2]
Synonyms	RNMAUIMMNAHKQR-QFBILLFUSA-N; BAY-1436032; 1803274-65-8; BAY 1436032; SCHEMBL17009632; EX-A1606; AKOS032946249; SB19763; HY-100020; CS-0017982; 3-(2-((4-(trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic acid Click to Show/Hide
External Link	CID: 118310260 TTD: D0C6RM
Compound Name	CD33-CAR-T Cell		Phase 1	[147]
External Link	TTD: D0C4GN
Compound Name	CART-123 cells		Phase 1	[135]
External Link	TTD: D0AW4T
Compound Name	FATE-NK100		Phase 1	[2]
External Link	TTD: D0A9GE
Compound Name	CC-90009		Phase 1	[2]
External Link	TTD: D09WIR
Compound Name	NKR-2 CAR-T Cells		Phase 1	[148]
External Link	TTD: D08YHE
Compound Name	Anti-CEA CAR-T cells		Phase 1	[149]
External Link	TTD: D08UVN
Compound Name	RG7775		Phase 1	[150]
External Link	TTD: D08TNG
Compound Name	OTSSP167		Phase 1	[2]
Synonyms	OTSSP 167; OTSSP-167; AMX10201 Click to Show/Hide
External Link	CID: 135398499 TTD: D08FIX
Compound Name	IMC-EB10		Phase 1	[151]
Synonyms	Anti-Flt-3 Mab Click to Show/Hide
External Link	TTD: D07ZNF
Compound Name	TCN-P		Phase 1	[152]
Synonyms	TRICIRIBINE PHOSPHATE; 61966-08-3; UNII-5L5GE3DV88; Triciribine phosphate [USAN]; Tricirbine Phosphate; NSC-280594; C13H17N6O7P; NSC 280594; Pentaazaacenaphthylene-5' phosphate ester; 5L5GE3DV88; PHOSPHATE SALT OF TRICYCLIC NUCLEOSIDE; 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene 5'-(dihydrogen phosphate); Triciribine phosphate (USAN); VQD-002; TCN-monophosphate; 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-; NSC280594 Click to Show/Hide
External Link	CID: 43860 TTD: D07TWK DrugBank: DB14636
Compound Name	CART-38 cells		Phase 1	[135]
External Link	TTD: D06OES
Compound Name	ABBV-744		Phase 1	[2]
Synonyms	OEDSFMUSNZDJFD-UHFFFAOYSA-N; 2138861-99-9; N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide; ABBV 744; SCHEMBL19463409; EX-A2713; ACN-054460; HY-112090; CS-0043318 Click to Show/Hide
External Link	CID: 132010322 TTD: D05ICT
Compound Name	AGS-67E		Phase 1	[10]
External Link	TTD: D04MBK
Compound Name	PNK-007		Phase 1	[10]
External Link	TTD: D03IRG
Compound Name	GSK-2130579A		Phase 1	[153]
Synonyms	Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline Click to Show/Hide
External Link	TTD: D02JEW
Compound Name	SGN-CD123A		Phase 1	[2]
External Link	TTD: D01BRD
Compound Name	IM23		Phase 1	[154]
External Link	TTD: D00HAN
Compound Name	Anti-CD33		Phase 1	[2]
External Link	TTD: D00DIB
Compound Name	KW-2449		Phase 1	[155]
Synonyms	Tumor antigen-specific mAb (cancer), Kyowa; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kirin; Tumor antigen-specific monoclonal antibody (cancer), Kyowa Hakko Kogyo Click to Show/Hide
External Link	CID: 11427553 TTD: D00ABO
Compound Name	CAR-T cells targeting CD56		Clinical trial	[156]
External Link	TTD: D0V6WW
Compound Name	CAR-T cells targeting CD38		Clinical trial	[156]
External Link	TTD: D0V6WU
Compound Name	Valspodar		Discontinued in Phase 3	[157]
External Link	CID: 5281884 TTD: D09TGX DrugBank: DB11869
Compound Name	LY335979		Discontinued in Phase 3	[158]
Synonyms	Zosuquidar HCl; Zosuquidar Trihydrochloride; LY 335979; LY-335979; Zosuquidar (TN); Zosuquidar trihydrochloride (USAN); RS-33295-198; Zosuquidar trihydrochloride, RS-33295-198, LY335979; (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride Click to Show/Hide
External Link	CID: 153997 TTD: D06DCL
Compound Name	Lintuzumab Bi-213		Discontinued in Phase 1/2	[159]
Synonyms	Bismab-A (TN) Click to Show/Hide
External Link	TTD: D0S1LE
Compound Name	HuM-195-Bi-213		Discontinued in Phase 1/2	[159]
Synonyms	SMART 213Bi-M195; SMART Y90-M195; Y90-HuM195; Bismuth-213-HuM195; SMART bismuth-213-M195; Yttrium-90-HuM195; Alpha-particle-emitting radioisotope-linked lintuzumab; 213Bi-HuM195 Click to Show/Hide
External Link	TTD: D0IJ1D
Compound Name	CER-227185		Discontinued in Phase 1/2	[160]
Synonyms	TCTP inhibitor (cancer), Cerenis; Translationally controlled tumor protein inhibitor (acute myeloid leukemia), Cerenis Click to Show/Hide
External Link	TTD: D01CEQ
Compound Name	Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes		Phase 0	[161]
External Link	TTD: D0H8UT
Compound Name	ATA2321		Preclinical	[162]
External Link	TTD: DI2X8V
Compound Name	2-D08		Preclinical	[163]
Synonyms	144707-18-6; 2',3',4'-trihydroxyflavone; 2-(2,3,4-trihydroxyphenyl)-4H-1-benzopyran-4-one; 2-(2,3,4-Trihydroxyphenyl)-4H-chromen-4-one; SCHEMBL1772778; CHEMBL3115475; AOB4275; SYN5001; AMY31051; BCP18314; EX-A3562; MFCD27995567; s8696; ZINC97439024; CCG-267148; AC-31428; AK312791; AS-16368; HY-114166; 2D08;2 D08; CS-0077855; A16852; 2-(2,3,4-TRIHYDROXYPHENYL)CHROMEN-4-ONE Click to Show/Hide
External Link	CID: 22507438 TTD: D4UFT5
Compound Name	CAR-T cells targeting CD117		Preclinical	[156]
External Link	TTD: D0TS2B
Compound Name	CAR-T cells targeting CD123		Preclinical	[156]
External Link	TTD: D0N4VG
Compound Name	CAR-T cells targeting Mucl		Preclinical	[156]
External Link	TTD: D0JW9E
Compound Name	CAR-T cells targeting CD33		Preclinical	[156]
External Link	TTD: D0JT0U
Compound Name	CAR-T cells targeting CD34		Preclinical	[156]
External Link	TTD: D08ABX
Compound Name	CAR-T cells targeting CD133		Preclinical	[156]
External Link	TTD: D04JSI
Compound Name	CEP-4186		Terminated	[164]
Synonyms	CB-1093; CEP-3265; GS-1590; Neurotrophic compounds, Cephalon/LEO Pharma; Neurotrophic factors, Cephalon/LEO Pharma Click to Show/Hide
External Link	TTD: D0T9SJ
Compound Name	BI 7273		Investigative	[165]
Synonyms	BI-7273; 1883429-21-7; CHEMBL3823478; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 4-[4-[(Dimethylamino)methyl]-3,5-Dimethoxy-Phenyl]-2-Methyl-2,7-Naphthyridin-1-One; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one; 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1(2H)-one; 5SW; BI7273; GTPL9146; SCHEMBL19869878; EX-A990; BCP17545; BDBM50183448; MFCD30489736; s8179; ZINC575448880; CCG-268068; CS-5887; HY-100351; J3.533.936A; A16068; Q27075221 Click to Show/Hide
External Link	CID: 118796358 TTD: DVZ6M1
Compound Name	G3139 + cytarabine (ARA-C)		Investigative	[166]
External Link	CID: 91865905 TTD: D0XU9F
Compound Name	G3139 + Fludarabine		Investigative	[166]
External Link	CID: 91865905 TTD: D0LM3T
Compound Name	CG-1255		Investigative	[167]
Synonyms	CG-1552; Histone deacetylase inhibitors, CircaGen Click to Show/Hide
External Link	TTD: D0J3QN
Compound Name	AC-501		Investigative	[167]
External Link	TTD: D0E1UY
Compound Name	AKN-028		Investigative	[168]
Synonyms	Flt3 tyrosine kinase inhibitor (AML), Akinion/Swedish Orphan Biovitrum/Karolinska Click to Show/Hide
External Link	CID: 44177328 TTD: D0D0TQ DrugBank: DB12746
Compound Name	VLIM-88		Investigative	[167]
External Link	TTD: D0B1TN
Compound Name	G3139 + G-CSF		Investigative	[166]
External Link	CID: 91865905 TTD: D0B0HK
Compound Name	Anti-CD44 mab		Investigative	[167]
Synonyms	Hyaloxan; MAT-102; AML therapy (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia (chimerized monoclonal antibody), MAT Biopharma; Acute myeloid leukemia therapy (chimerized monoclonal antibody), MAT Biopharma; Anti-CD44 mAb (AML); Anti-CD44 mAb (AML), MAT Biopharma; Anti-CD44 monoclonal antibody (acute myeloid leukemia), MAT Biopharma Click to Show/Hide
External Link	TTD: D0A9JA
Compound Name	SB-559457		Investigative	[169]
External Link	TTD: D09WOY
Compound Name	COTI-001		Investigative	[167]
Synonyms	COTI-002; COTI-003E; Protein tyrosine kinase inhibitors (AML); Protein tyrosine kinase inhibitors (AML), Critical Outcome Technologies Click to Show/Hide
External Link	TTD: D04BXH
Compound Name	Rebelex		Investigative	[167]
Synonyms	Spleen tyrosine kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals; Syk kinase inhibitor (siRNA/oligonucleotide, acute myelogenous leukemia), Biothorpe Pharmaceuticals Click to Show/Hide
External Link	TTD: D01UJS

References

Ref 1	Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1. Daru. 2024 Jun;32(1):11-24. doi: 10.1007/s40199-023-00482-y. Epub 2023 Nov 6.
Ref 2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3	2017 FDA drug approvals. Nat Rev Drug Discov. 2018 Feb;17(2):81-85. doi: 10.1038/nrd.2018.4. Epub 2018 Jan 19.
Ref 4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
Ref 5	ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
Ref 6	2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5151).
Ref 9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
Ref 10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
Ref 12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6775).
Ref 14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6845).
Ref 15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
Ref 16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
Ref 17	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 18	ClinicalTrials.gov (NCT04778397) Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2). U.S. National Institutes of Health.
Ref 19	ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
Ref 20	ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health.
Ref 21	ClinicalTrials.gov (NCT04571645) Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML). U.S. National Institutes of Health.
Ref 22	ClinicalTrials.gov (NCT01006252) A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma. U.S. National Institutes of Health.
Ref 23	ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health.
Ref 24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8086).
Ref 25	ClinicalTrials.gov (NCT02348489) SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction. U.S. National Institutes of Health.
Ref 26	ClinicalTrials.gov (NCT01147939) Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML). U.S. National Institutes of Health.
Ref 27	ClinicalTrials.gov (NCT02545283) A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (MIRROS). U.S. National Institutes of Health.
Ref 28	ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.
Ref 29	ClinicalTrials.gov (NCT02273739) Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation. U.S.National Institutes of Health.
Ref 30	ClinicalTrials.gov (NCT01303796) A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 31	ClinicalTrials.gov (NCT01478178) Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.
Ref 32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011613)
Ref 33	ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 34	ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 35	ClinicalTrials.gov (NCT00522834) Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma. U.S. National Institutes of Health.
Ref 36	ClinicalTrials.gov (NCT03616470) Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
Ref 38	Therapeutic Vaccines against Cancer: Clinical trials of therapeutic vaccines in cancer patients yield positive results. OncoLog, August 2010, Vol.55, No.8.
Ref 39	ClinicalTrials.gov (NCT01191801) Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (VALOR). U.S. National Institutes of Health.
Ref 40	ClinicalTrials.gov (NCT03699475) Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE). U.S. National Institutes of Health.
Ref 41	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
Ref 42	ClinicalTrials.gov (NCT04395092) Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). U.S. National Institutes of Health.
Ref 43	ClinicalTrials.gov (NCT03301597) NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH). U.S. National Institutes of Health.
Ref 44	ClinicalTrials.gov (NCT03110354) DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). U.S. National Institutes of Health.
Ref 45	ClinicalTrials.gov (NCT04827719) BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS. U.S. National Institutes of Health.
Ref 46	ClinicalTrials.gov (NCT04511130) A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation. U.S.National Institutes of Health.
Ref 47	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7958).
Ref 48	ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Ref 49	ClinicalTrials.gov (NCT01416389) A Study of LY2523355 in Patients With Breast Cancer. U.S. National Institutes of Health.
Ref 50	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885).
Ref 52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040574)
Ref 53	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5666).
Ref 54	ClinicalTrials.gov (NCT01463696) Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650). U.S. National Institutes of Health.
Ref 55	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
Ref 56	ClinicalTrials.gov (NCT03760666) A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 57	ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
Ref 59	ClinicalTrials.gov (NCT00210470) A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer. U.S. National Institutes of Health.
Ref 60	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8270).
Ref 61	ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Ref 62	ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 63	The enhancement of phase 2 enzyme activities by sodium butyrate in normal intestinal epithelial cells is associated with Nrf2 and p53. Mol Cell Biochem. 2012 Nov;370(1-2):7-14.
Ref 64	ClinicalTrials.gov (NCT00510133) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
Ref 65	ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
Ref 66	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022187)
Ref 67	Clinical pipeline report, company report or official report of Asterias.
Ref 68	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 437).
Ref 69	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 70	Iomab-B for Hematopoetic Stem Cells Transplantation. Pipeline report of Actinium Pharmaecuticals. 2012.
Ref 71	ClinicalTrials.gov (NCT00559871) Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease. U.S. National Institutes of Health.
Ref 72	ClinicalTrials.gov (NCT00544674) PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 73	ClinicalTrials.gov (NCT00363649) Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI. U.S. National Institutes of Health.
Ref 74	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
Ref 75	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7708).
Ref 76	ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
Ref 77	ClinicalTrials.gov (NCT04079296) A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
Ref 78	ClinicalTrials.gov (NCT04477291) A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 79	ClinicalTrials.gov (NCT04067336) First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 80	ClinicalTrials.gov (NCT03594955) First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 81	ClinicalTrials.gov (NCT03850574) Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 82	ClinicalTrials.gov (NCT03176277) A Study of ONO-7475 in Patients With Acute Leukemias. U.S. National Institutes of Health.
Ref 83	ClinicalTrials.gov (NCT03194685) Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 84	ClinicalTrials.gov (NCT02113982) SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 85	ClinicalTrials.gov (NCT03008187) SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 86	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Ref 87	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 88	ClinicalTrials.gov (NCT04284228) Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT. U.S. National Institutes of Health.
Ref 89	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
Ref 90	ClinicalTrials.gov (NCT01606579) Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies. U.S. National Institutes of Health.
Ref 91	ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
Ref 92	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021304)
Ref 93	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017917)
Ref 94	ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Ref 95	ClinicalTrials.gov (NCT03701295) Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement. U.S. National Institutes of Health.
Ref 96	ClinicalTrials.gov (NCT00397579) DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes. U.S. National Institutes of Health.
Ref 97	ClinicalTrials.gov (NCT04493619) PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 98	ClinicalTrials.gov (NCT03055286) Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. U.S. National Institutes of Health.
Ref 99	ClinicalTrials.gov (NCT04372706) RTX-240 Monotherapy. U.S. National Institutes of Health.
Ref 100	Clinical pipeline report, company report or official report of Genus 0ncology.
Ref 101	ClinicalTrials.gov (NCT02303782) A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT). U.S. National Institutes of Health.
Ref 102	CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018 Jul 24;2(14):1738-1749.
Ref 103	ClinicalTrials.gov (NCT03841110) FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 104	ClinicalTrials.gov (NCT03705858) Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 105	ClinicalTrials.gov (NCT03927261) A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome. U.S.National Institutes of Health.
Ref 106	ClinicalTrials.gov (NCT03516760) Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 107	ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
Ref 108	ClinicalTrials.gov (NCT04021368) SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 109	ClinicalTrials.gov (NCT04623944) NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS. U.S. National Institutes of Health.
Ref 110	ClinicalTrials.gov (NCT05086315) An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Adult and Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). U.S.National Institutes of Health.
Ref 111	ClinicalTrials.gov (NCT04372433) IO-202 as Monotherapy in Patients in AML and CMML. U.S. National Institutes of Health.
Ref 112	ClinicalTrials.gov (NCT03884829) A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS. U.S. National Institutes of Health.
Ref 113	ClinicalTrials.gov (NCT03564288) Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 114	ClinicalTrials.gov (NCT04282668) A Study of TAS1440 With ATRA in Subjects With r/r AML. U.S. National Institutes of Health.
Ref 115	Clinical pipeline report, company report or official report of Roche
Ref 116	ClinicalTrials.gov (NCT04402541) Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 117	ClinicalTrials.gov (NCT05712278) A Phase I, Single-arm, Open Label, Dose Escalation, Multicenter Study of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). U.S.National Institutes of Health.
Ref 118	ClinicalTrials.gov (NCT03483324) Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation. U.S. National Institutes of Health.
Ref 119	ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
Ref 120	ClinicalTrials.gov (NCT02841540) A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. U.S. National Institutes of Health.
Ref 121	ClinicalTrials.gov (NCT04156256) CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies. U.S. National Institutes of Health.
Ref 122	ClinicalTrials.gov (NCT03915379) A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health.
Ref 123	ClinicalTrials.gov (NCT03541369) Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528). U.S. National Institutes of Health.
Ref 124	ClinicalTrials.gov (NCT04272203) A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers. U.S. National Institutes of Health.
Ref 125	ClinicalTrials.gov (NCT02979366) Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome. U.S. National Institutes of Health.
Ref 126	ClinicalTrials.gov (NCT04614636) FT538 in Subjects With Advanced Hematologic Malignancies. U.S. National Institutes of Health.
Ref 127	ClinicalTrials.gov (NCT04771130) A Study of BGB-11417 in Participants With Myeloid Malignancies. U.S. National Institutes of Health.
Ref 128	ClinicalTrials.gov (NCT04227847) A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies. U.S. National Institutes of Health.
Ref 129	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
Ref 130	ClinicalTrials.gov (NCT04789408) A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia. U.S.National Institutes of Health.
Ref 131	ClinicalTrials.gov (NCT04167696) Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1). U.S. National Institutes of Health.
Ref 132	ClinicalTrials.gov (NCT05001451) A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia. U.S.National Institutes of Health.
Ref 133	ClinicalTrials.gov (NCT03647800) Study of APVO436 in Patients With AML or MDS. U.S. National Institutes of Health.
Ref 134	ClinicalTrials.gov (NCT02305563) Phase 1 Study of BMS-936564. U.S. National Institutes of Health.
Ref 135	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Ref 136	A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.
Ref 137	ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
Ref 138	ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases
Ref 139	ClinicalTrials.gov (NCT00701324) BI 811283 in Various Solid Tumours. U.S. National Institutes of Health.
Ref 140	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
Ref 141	ClinicalTrials.gov (NCT02040506) A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML. U.S. National Institutes of Health.
Ref 142	ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Ref 143	ClinicalTrials.gov (NCT00981240) Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes. U.S. National Institutes of Health.
Ref 144	ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Ref 145	ClinicalTrials.gov (NCT01632852) A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission. U.S. National Institutes of Health.
Ref 146	ClinicalTrials.gov (NCT03797261) A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies. U.S. National Institutes of Health.
Ref 147	ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Ref 148	ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Ref 149	ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Ref 150	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040360)
Ref 151	ClinicalTrials.gov (NCT00887926) Study of EB10 in Patients With Leukemia. U.S. National Institutes of Health.
Ref 152	ClinicalTrials.gov (NCT00363454) Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer. U.S. National Institutes of Health.
Ref 153	ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health.
Ref 154	ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
Ref 155	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5691).
Ref 156	ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Ref 157	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001281)
Ref 158	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005159)
Ref 159	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008571)
Ref 160	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026293)
Ref 161	ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML
Ref 162	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
Ref 163	2-D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1063-1069.
Ref 164	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012493)
Ref 165	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75.
Ref 166	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
Ref 167	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 168	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7969).
Ref 169	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map